Form D · Biotechnology
Revelation Biosciences, Inc
San Diego, CA · CIK 0001812479
Offering snapshot reported May 4, 2021 · SEC filing
- Reported sold
- $5.14M Offering amount: $5.14M
- Investors reported
- 44 Form D · investor count
- Minimum accepted
- $5.03K Reported outside-investor minimum
- First sale
- Jan 4, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 4, 2021 | Initial | $5,144,458 | No comparison | 44 | SEC filing |
| Apr 23, 2021 | Amendment | $4,353,102 | $0vs Apr 22, 2021 | 61 | SEC filing |
| Apr 22, 2021 | Initial | $4,353,102 | No comparison | 61 | SEC filing |
| Jul 6, 2020 | Initial | $1,001,290 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-398081
Source: Form D, filed May 4, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jennifer Carver | Director |
| Curt La Belle | Director |
| James M. Rolke | Director, Executive |
| Jess Roper | Director |
| George F. Tidmarsh | Director |
| Chester S. Zygmont | Executive |
| Chester S. Zygmont Iii | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4660 Lajolla Village Drive Suite 100
San Diego, CA, 92122
San Diego, CA, 92122